hempfusion stock

HempFusion Reports Q2, 2021 Financial Results

Year Over Year Revenues Up 84%, Q2 net revenues up 25% sequentially over Q1 and Year Over Year Ecommerce Sales Up 268%

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) ("HempFusion" or the "Company"), an industry leader in full spectrum cannabidiol (CBD) hemp extract wellness products and probiotics, today reported financial results for the second quarter ended June 30, 2021. All dollars are stated in US Dollars.

"With year over year growth in net revenues of 84%, year over year direct to consumer ecommerce revenues up 268%, and our leading regulatory preparedness, HempFusion's momentum shows it to be the right company, at the right time, to lead this new category into the future," stated Dr. Jason Mitchell, HempFusion CEO. "Additionally, subsequent to the quarter end, the Company closed on two accretive acquisitions and highly respected CBD brands, adding significant new distribution points and products," continued Mr. Mitchell.

Second Quarter 2021 Financial Highlights

  • Revenue increased 25% to over $1.2 million for Q2 2021 compared to $983,496 in Q1 2021 and increased 84% compared to $670,728 in Q2 2020.
  • Direct-to-consumer eCommerce sales increased 37% to $334,322 from $244,255 in Q1. Website based sales increased 54% and DTC including Amazon, Walmart and Tmall increased 23% sequentially in Q2.
  • B2B net revenue increased 22% to $898,620 in Q2 2021 from $739,241 in Q1 2021 and a 55% increase year-on-year compared to $579,910 in Q2 2020.
  • International sales began to return following Covid, increasing by 68% to $203,296 in Q2 2021 from $75,994 in Q1 2021.
  • Launched private label division and were immediately awarded a 10-product private label contract with a top publiclytraded national grocery retailer. We believe this division could represent multi million dollars in revenue within the next few years for both CBD and non-CBD products.
  • Gross profit was $232,417 or 19% of net revenue versus -19% in the prior year quarter, representing a 38% improvement reflective of more effective inventory management and improvements in managing production costs.
  • Operating expenses were $6,568,503, an increase of 4% from $6,306,703 in Q1 2021, primarily attributed to acquisition related expenses as well as marketing and digital related expenses.
  • Strong cash position ending the quarter at $11.4 million.

Second Quarter 2021 Business Highlights

  • The Company launched its highly anticipated CBD Gummy line in early August 2021, utilizing HempFusion's proprietary broad-spectrum hemp extract, never an isolate. The gummies feature natural functional ingredients and premium flavors, two popular consumer driven trends. According to Brightfield Group, the CBD gummy market is set to achieve $500 million in sales in 2021, up 44% from 2020, and is expected to reach $1.8 billion in 2026.
  • In June 2021, HempFusion launched its new EU compliant Probulin in Boots Pharmacies in Ireland, establishing a foundation for further opportunities and expansion in retailers across Ireland, the United Kingdom and Europe. Boots Ireland is part of the Retail Pharmacy International Division of one of the world's largest purchasers of prescription drugs and many other health and well-being products, with one of the largest retail footprints in the world.
  • In early June 2021, HempFusion launched its sixth distribution channel, Private Label. The Company secured a 10 SKU private label deal with a leading national publicly traded grocery retailer. The initial order for approximately $250,000 was shipped in July 2021. The Company anticipates this particular account to generate north of $500,000 for 2021 and approximately $1 million or more in 2022.
  • HempFusion's ecommerce business is growing. New customer acquisition increased online by 69.7% over Q1, 2021, and not only did online increase for both Probulin and HempFusion, but traffic increased by 46.06% over Q1, 2021. Probulin's average conversion rate has remained very strong and consistent at 3.21%, and HempFusion has demonstrated a dramatic increase now at 4.37%.
  • In May 2021, HempFusion announced an exclusive partnership with two-time Olympic Gold Medalist and five-time World Champion, Kaillie Humphries. HempFusion CBD and Probulin Probiotics will be Kaillie's exclusive sponsors in their respective categories through February's Olympic Games in Beijing 2022 where she is the front-runner for gold for Team USA in both the Two-woman Bobsled and the newly introduced Women's Monobob.
  • Subsequent to the quarter end, HempFusion completed both of the previously announced acquisitions of Sagely Enterprises Inc. (Sagely Naturals) and APCNA Holdings LLC (Apothecanna). These acquisitions greatly expand the distribution footprint of the Company to over 15,000 locations providing the opportunity to expand with ingestible products. The complimentary product lines also provide the combined entity with a broader coverage of demographics.

Statements of Loss and Comprehensive Loss

The Below is from the Unaudited Condensed Interim Financial Statements for the Three and Six Months Ended June 30, 2021 and 2020; Please Refer to the Complete Report, Including the Notes, Other Statements and Other Contents Therein.

For the three

For the three

For the six

For the six

months ended

months ended

months ended

months ended

June 30,

June 30,

June 30,

June 30,

2021

2020

2021

2020

$

$

$

$

Revenue, net of discounts

1,232,942

670,728

2,216,438

1,681,303

Cost of goods sold

1,000,525

800,294

1,919,413

1,724,482

Gross profit (loss)

232,417

(129,566

)

297,025

(43,179

)

Expenses
General and administrative Note 15

2,894,723

1,910,788

5,549,857

4,066,990

Sales and marketing

3,673,780

1,463,003

7,325,349

3,760,593

Total expenses

6,568,503

3,373,791

12,875,206

7,827,583

Net loss from operations

(6,336,086

)

(3,503,357

)

(12,578,181

)

(7,870,762

)

Other (income) expenses
Other (income)

(10,610

)

(6,500

)

(113,075

)

(71,768

)

Interest expense

4,464

16,714

9,247

24,296

Change in fair value of derivative liabilities Note 11

100,279

35,892

Gain on derecognition of derivative liabilities

(70,809

)

Change in fair value of purchase consideration Note 4

203,710

77,280

167,368

254,555

Total other (income) expenses

197,564

187,773

(7,269

)

242,975

Net loss and comprehensive loss

(6,533,650

)

(3,691,130

)

(12,570,912

)

(8,113,737

)

Loss per common share - basic and diluted

(0.06

)

(0.04

)

(0.11

)

(0.08

)

Weighted average number of common shares - basic and diluted

116,852,879

99,699,196

116,852,879

99,699,196

Consolidated net revenue for the three months ended June 30, 2021 increased 84% year-over-year to $1,232,942 versus $670,728 in Q2-2020, and increased 25% over Q1-2021, and DTC e-commerce net sales year-over-year increased 268% reflecting increased marketing efforts, a targeted DTC team, and targeted digital promotions. New customer acquisition increased online by 69.7% over Q1, 2021, and not only did online increase for both Probulin and HempFusion, but traffic increased by 46.% over Q1, 2021. Probulin's average conversion rate has remained very strong and consistent at 3.21%, and HempFusion has demonstrated a dramatic increase now at 4.37%.

Consolidated B2B net revenue increased 55% to $898,620 in Q2 2021 from $579,910in Q2-2020 and B2B net revenue increased by 22% to $898, 620 in Q2 2021 from $739,241 in Q1 2021. International sales began to return following Covid, increasing by 68% to $203,296 in Q2 2021 from $75,994 in Q1-2021. HempFusion maintains a leadership position in retailers across the United States, including the #1 in sales by dollar volume and unit sales in one of the top five largest FDM channel retailers.

Gross profit of $232,417 or 19% up from -19% in Q2 2020 of net revenue is primarily attributed to improvement in inventory and supply chain management. These efforts continue to make large improvements.

Operating expenses were $6,568,503, an increase of 95% from $3,373,791 in Q2-2020, primarily attributed to acquisition related expenses, as well as marketing and digital expenses.

Balance Sheet | Cash Position

The Below is from the Unaudited Condensed Interim Financial Statements for the Three Months Ended June 30, 2021 and 2020; Please Refer to the Complete Report, Including the Notes, Other Statements and Other Contents Therein.

June 30, December 31,

2021

2020

$ $ (Audited)
ASSETS
Current
Cash

11,370,824

9,262,517

Trade receivables Note 5

467,657

457,058

Inventory Note 6

2,831,938

2,576,866

Prepayments Note 7

1,596,179

1,530,846

16,266,598

13,827,287

Property and equipment Note 8

295,229

303,162

Right-of-use-assets Note 9

196,100

225,589

Prepayments - non current Note 7

242,815

Total assets

17,000,742

14,356,038

LIABILITIES
Current
Accounts payable and accrued liabilities Note 10

1,583,636

2,324,534

Derivative liabilities Note 11

13,975,514

Lease obligations Note 9

63,144

60,279

Purchase consideration payable Note 4

1,534,467

1,367,099

3,181,247

17,727,426

Non-current
Lease obligations Note 9

132,956

165,310

Total liabilities

3,314,203

17,892,736

SHAREHOLDERS' EQUITY (DEFICIT)
Share capital Note 11

57,590,356

45,002,867

Warrant reserve Note 11

17,206,393

1,572,556

Contributed surplus Notes 11 and 12

5,378,700

3,805,877

Accumulated deficit

(66,488,910

)

(53,917,998

)

Total equity (deficit)

13,686,539

(3,536,698

)

Total liabilities and shareholders' equity

17,000,742

14,356,038

The Company ended Q2-2021 with a strong cash position of $11,370,824. Incurring $2,894,723 in general and administrative expenses and $3,673,780 in sales and marketing expenses.

Management of the Company will host a conference call to discuss the Company's second quarter 2021 results on Monday, August 16, 2021 at 8:30 a.m. (Eastern Time). To participate in the call, please dial 888-506-0062. For international callers, please dial 973-528-0011. Use Entry Code: 746381. To join the webcast, please visit https://www.webcaster4.com/Webcast/Page/2710/42495

A replay will be available from the Investor Relations section of HempFusion's website at HempFusion.com/corporate-information .

ABOUT HEMPFUSION

HempFusion is a leading health and wellness CBD Company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to over approximately 15,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion's diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion's wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion's CBD products are based on a proprietary Whole Food Hemp Complex™ and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com .

Follow HempFusion on Twitter , Facebook and Instagram and Probulin on Twitter , Facebook and Instagram .

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, " forward-looking statements ") that relate to HempFusion's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result", "are expected to", "expects", "will continue", "is anticipated", "anticipates", "believes", "estimated", "intends", "plans", "forecast", "projection", "strategy", "objective" and "outlook") are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward-looking statements relating to the continued growth of the Company's international business and revenue, the Company's plans to accelerate sales, DTC sales expectations, anticipated growth of the Company's private label division, including private label orders from the noted leading national publicly traded grocery retailer, expansion opportunities for the Company's ingestible products and the Company's other plans, focus and objectives.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond HempFusion's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under " Cautionary Note Regarding Forward-Looking Statements " and " Risk Factors " in the annual information form of the Company dated March 31, 2021 and available under the Company's profile on SEDAR at www.sedar.com . HempFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for HempFusion to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Jason Mitchell, N.D.
Chief Executive Officer and Director
Email: ir@hempfusion.com
Phone: 416-803-5638

News Provided by Business Wire via QuoteMedia

The Conversation (0)
  BPH Global Ltd

120-Day Business Development Plan

The Board of BPH Global Ltd (ASX: BP8) (Company) announces that the Company’s CEO Matthew Leonard and CFO Chow Yee Koh are currently travelling in Malaysia and China for a series of meetings over a 2–3- week period commencing last week. The CEO and CFO will be joined by China-based Company Director Michael Huang for strategic meetings in Malaysia and China.

Keep reading...Show less
  BPH Global Ltd

BP8 to Expand Seaweed R&D Activities into Essential Mineral Extraction Utilising AI Search Technology; Carbon Credits

The Board of BPH Global Ltd (ASX: BP8) (Company) is pleased to announce that the Company is expanding the nature of its business to include the following projects:

Keep reading...Show less
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions.

The chosen formulation will not only define the brand but also lay the foundation for a broader range of products. The team is in the process of selecting the precise formulation that will undergo standard safety evaluations and be used in the upcoming clinical trial. This is in preparation for the planned product launch in early 2025, ensuring compliance with regulatory standards in the European, US, and Canadian markets.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
double helix molecule with word "etf"

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to gain leverage in multiple biotech companies via one investment vehicle.

The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

Below the Investing News Network takes a look at five small biotech ETFs for investors to consider. They were selected using ETFdb.com, and their total assets under management (AUM) were under US$100 million as of March 8, 2024. All other figures were also current as of that date. Read on to learn more about these investment vehicles.

Keep reading...Show less

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® AT AAD 2024

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis

Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2024

Investing in the biotech industry can be a long road to gains given the sector’s volatility.

Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded funds (ETFs) a more secure option than individual biotech stocks.

An ETF is a relatively safe investment route that can minimize losses while offering exposure to multiple companies instead of focusing on the gains and losses of a single biotech stock. With that in mind, here’s a brief look at the five top biotechnology ETFs by total assets. Data was sourced from ETFdb.com on March 1, 2024, and all data was current as of that time.

Keep reading...Show less

Latest Press Releases

Related News

×